Abstract Objective To investigate the role of calprotectin S100 A8/A9 complex in evaluating the condition of children with severe Mycoplasma pneumoniae pneumonia (SMPP). Methods A prospective study was conducted among 136 children with Mycoplasma pneumoniae pneumonia (MPP) and 30 healthy controls. According to the severity of the condition, the children with MPP were divided into mild subgroup (40 children) and SMPP subgroup (96 children). The levels of S100 A8/A9 complex and related inflammatory factors were compared between the MPP group and the healthy control group, as well as between the two subgroups of MPP. The role of S100 A8/A9 in assessing the severity of MPP was explored. Results The MPP group had a significantly higher level of S100 A8/A9 than the healthy control group, with a significantly greater increase in the SMPP subgroup (P<0.05). The multivariate logistic regression analysis showed that the increases in serum C reactive protein (CRP) and S100A8/A9 were closely associated with SMPP (P<0.05). The receiver operating characteristic (ROC) curve analysis showed that the combined measurement of serum S100 A8/A9 and CRP had an area under the ROC curve of 0.904 in predicting SMPP, which was significantly higher than the AUC of S100 A8/A9 or CRP alone (P<0.05), with a specificity of 0.718 and a sensitivity of 0.952. Conclusions S100 A8/A9 is closely associated with the severity of MPP, and the combination of S100 A8/A9 with CRP is more advantageous for assessing the severity of MPP in children.
ZHOU Pei,PENG Li,XU Lu et al. Value of calprotectin S100 A8/A9 in predicting the severity of Mycoplasma pneumoniae pneumonia in children[J]. CJCP, 2024, 26(7): 716-722.
ZHOU Pei,PENG Li,XU Lu et al. Value of calprotectin S100 A8/A9 in predicting the severity of Mycoplasma pneumoniae pneumonia in children[J]. CJCP, 2024, 26(7): 716-722.
Xie S, Wang J, Tuo W, et al. Serum level of S100A8/A9 as a biomarker for establishing the diagnosis and severity of community-acquired pneumonia in children[J]. Front Cell Infect Microbiol, 2023, 13: 1139556. PMID: 37180431. PMCID: PMC10172663. DOI: 10.3389/fcimb.2023.1139556.
Liu B, Chang X, Yan N. Clinical analysis of the epidemiology and changes in inflammatory indexes of Mycoplasma pneumonia in acute and recovery stage pediatric patients[J]. Transl Pediatr, 2022, 11(10): 1645-1655. PMID: 36345443. PMCID: PMC9636459. DOI: 10.21037/tp-22-416.
Otheo E, Rodríguez M, Moraleda C, et al. Viruses and Mycoplasma pneumoniae are the main etiological agents of community-acquired pneumonia in hospitalized pediatric patients in Spain[J]. Pediatr Pulmonol, 2022, 57(1): 253-263. PMID: 34633153. DOI: 10.1002/ppul.25721.
Fang C, Mao Y, Jiang M, et al. Pediatric Critical Illness Score, clinical characteristics and comprehensive treatment of children with severe Mycoplasma pneumoniae pneumonia[J]. Front Surg, 2022, 9: 897550. PMID: 35693303. PMCID: PMC9174934. DOI: 10.3389/fsurg.2022.897550.
Lee KL, Lee CM, Yang TL, et al. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019[J]. J Formos Med Assoc, 2021, 120(1 Pt 1): 281-291. PMID: 32948415. DOI: 10.1016/j.jfma.2020.08.018.
Wang J, Mao J, Chen G, et al. Evaluation on blood coagulation and C-reactive protein level among children with Mycoplasma pneumoniae pneumonia by different chest imaging findings[J]. Medicine (Baltimore), 2021, 100(3): e23926. PMID: 33545964. PMCID: PMC7837868. DOI: 10.1097/MD.0000000000023926.
Zhang C, Zhang Q, Du JL, et al. Correlation between the clinical severity, bacterial load, and inflammatory reaction in children with Mycoplasma pneumoniae pneumonia[J]. Curr Med Sci, 2020, 40(5): 822-828. PMID: 33123897. PMCID: PMC7595045. DOI: 10.1007/s11596-020-2261-6.
Fernandes CD, Arriaga MB, Costa MCM, et al. Host inflammatory biomarkers of disease severity in pediatric community-acquired pneumonia: a systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(12): ofz520. PMID: 31867405. PMCID: PMC6917028. DOI: 10.1093/ofid/ofz520.
Tian F, Chen LP, Yuan G, et al. Differences of TNF-α, IL-6 and gal-3 in lobar pneumonia and bronchial pneumonia caused by Mycoplasma pneumoniae[J]. Technol Health Care, 2020, 28(6): 711-719. PMID: 32200365. DOI: 10.3233/THC-192011.
Jin X, Zhu Y, Zhang Y, et al. Assessment of levels of D-dimer and interferon-γ in pediatric patients with Mycoplasma pneumoniae pneumonia and its clinical implication[J]. Exp Ther Med, 2018, 16(6): 5025-5030. PMID: 30546408. PMCID: PMC6256836. DOI: 10.3892/etm.2018.6873.
Bai S, Wang W, Ye L, et al. IL-17 stimulates neutrophils to release S100A8/A9 to promote lung epithelial cell apoptosis in Mycoplasma pneumoniae-induced pneumonia in children[J]. Biomed Pharmacother, 2021, 143: 112184. PMID: 34562768. DOI: 10.1016/j.biopha.2021.112184.